Malaysian (KLSE) Pharma Industry Analysis

UpdatedApr 01, 2026

DataAggregated Company Financials

Companies5

7D-3.2%
3M0.2%
1Y2.7%
YTDn/a

Over the last 7 days, the Pharma industry has dropped 3.2%, driven by a pullback from Duopharma Biotech Berhad of 3.7%. As for the longer term, the industry's performance has been flat for the past year. Looking forward, earnings are forecast to grow by 8.6% annually.

Industry Valuation and Performance

Has the Malaysian Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Wed, 01 Apr 2026	RM 2.3b	RM 1.9b	RM 169.4m	14x	13.8x	1.2x
Fri, 27 Feb 2026	RM 2.6b	RM 1.9b	RM 166.2m	14.6x	15.4x	1.4x
Sun, 25 Jan 2026	RM 4.3b	RM 2.8b	RM 231.9m	14.8x	18.5x	1.5x
Tue, 23 Dec 2025	RM 4.2b	RM 2.8b	RM 231.9m	14.5x	18.3x	1.5x
Thu, 20 Nov 2025	RM 4.2b	RM 2.8b	RM 230.6m	14.6x	18.2x	1.5x
Sat, 18 Oct 2025	RM 4.1b	RM 2.8b	RM 223.3m	15.2x	18.3x	1.5x
Mon, 15 Sep 2025	RM 4.2b	RM 2.8b	RM 223.3m	16.1x	18.9x	1.5x
Wed, 13 Aug 2025	RM 4.2b	RM 2.8b	RM 230.3m	15.7x	18.2x	1.5x
Fri, 11 Jul 2025	RM 4.1b	RM 2.8b	RM 230.3m	15.9x	18x	1.5x
Sun, 08 Jun 2025	RM 4.0b	RM 2.8b	RM 230.3m	16x	17.5x	1.4x
Tue, 06 May 2025	RM 3.9b	RM 2.8b	RM 221.0m	17x	17.8x	1.4x
Thu, 03 Apr 2025	RM 3.8b	RM 2.8b	RM 221.0m	16.5x	17.3x	1.4x
Sat, 01 Mar 2025	RM 3.9b	RM 2.8b	RM 223.1m	16.3x	17.7x	1.4x
Mon, 27 Jan 2025	RM 4.1b	RM 2.7b	RM 223.9m	16.7x	18.1x	1.5x
Wed, 25 Dec 2024	RM 4.2b	RM 2.7b	RM 223.9m	17.5x	18.5x	1.5x
Fri, 22 Nov 2024	RM 4.2b	RM 2.7b	RM 234.3m	14.7x	18.1x	1.5x
Sun, 20 Oct 2024	RM 4.5b	RM 2.7b	RM 230.0m	14.5x	19.4x	1.6x
Tue, 17 Sep 2024	RM 4.2b	RM 2.7b	RM 230.0m	14.4x	18.5x	1.6x
Thu, 15 Aug 2024	RM 4.2b	RM 2.6b	RM 541.5m	12.3x	7.8x	1.6x
Sat, 13 Jul 2024	RM 4.5b	RM 2.6b	RM 541.3m	13x	8.3x	1.7x
Mon, 10 Jun 2024	RM 4.6b	RM 2.6b	RM 541.3m	13.2x	8.5x	1.8x
Wed, 08 May 2024	RM 4.8b	RM 2.6b	RM 559.3m	12.5x	8.6x	1.8x
Fri, 05 Apr 2024	RM 4.6b	RM 2.6b	RM 559.3m	12.3x	8.2x	1.7x
Sun, 03 Mar 2024	RM 4.5b	RM 2.6b	RM 559.3m	12.5x	8x	1.7x
Tue, 30 Jan 2024	RM 4.5b	RM 2.6b	RM 584.9m	12.3x	7.6x	1.7x
Thu, 28 Dec 2023	RM 4.2b	RM 2.6b	RM 584.9m	12.3x	7.2x	1.6x
Sat, 25 Nov 2023	RM 4.2b	RM 2.6b	RM 591.7m	12.3x	7.1x	1.6x
Mon, 23 Oct 2023	RM 4.2b	RM 2.6b	RM 604.4m	12x	7x	1.6x
Wed, 20 Sep 2023	RM 4.3b	RM 2.6b	RM 604.4m	12.4x	7.1x	1.7x
Fri, 18 Aug 2023	RM 4.5b	RM 2.6b	RM 304.2m	13.9x	14.7x	1.7x
Sun, 16 Jul 2023	RM 4.3b	RM 2.6b	RM 304.7m	14.4x	14.1x	1.7x
Tue, 13 Jun 2023	RM 4.4b	RM 2.6b	RM 304.7m	14.5x	14.6x	1.7x
Thu, 11 May 2023	RM 4.6b	RM 2.5b	RM 289.8m	13.3x	15.9x	1.8x
Sat, 08 Apr 2023	RM 4.8b	RM 2.5b	RM 289.8m	13.3x	16.6x	1.9x

Price to Earnings Ratio

16.6x

Sat, 08 Apr 2023

Current Industry PE

Investors are relatively neutral on the Malaysian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.

The industry is trading close to its 3-year average PE ratio of 14.1x.

The 3-year average PS ratio of 1.6x is higher than the industry's current PS ratio of 1.2x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have declined 16% per year over the last three years,
Revenues have also declined 9.0% per year.
This means overall sales from these companies are declining and profits are subsequently falling as well.